Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
The new sharewise is here Clearer, faster, with a light and a dark view — and everything you already know. Try it now
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Kymera Therapeutics Stock Popped This Week

TheMotleyFool 
0 0 27.06.26
Why Kymera Therapeutics Stock Popped This Week: https://g.foolcdn.com/editorial/images/876620/two-people-in-white-lab-coats-looking-at-a-computer-display.jpg
 

This week was an eventful one for Kymera Therapeutics (NASDAQ: KYMR). The clinical-stage biotech announced the early completion of enrollment in an important clinical trial. It also earned a clutch of analyst price target raises. These developments were tempered by news of an insider stock sale.

Regardless, by Friday's market close, Kymera had risen by almost 30% over the five trading days, according to data compiled by S&P Global Market Intelligence.

Kymera, which specializes in medicines that use a process called targeted protein degradation (TPD), announced Thursday morning that it completed enrollment in a global Phase 2b trial of its leading drug candidate. This is KT-621, which will be tested in a trial to assess its efficacy in treating severe atopic dermatitis, a chronic skin condition.

Continue reading


Source Fool.com

Kt Corporation ADR Stock

€15.60
-0.640%
The price for the Kt Corporation ADR stock decreased slightly today. Compared to yesterday there is a change of -€0.100 (-0.640%).

Show more
Like: 0
KYMR
Share

Comments

Not a member yet? Sign up for free!